$42.03
-0.45 (-1.06%)
Open$42.14
Previous Close$42.48
Day High$42.47
Day Low$41.58
52W High$50.88
52W Low$34.89
Volume—
Avg Volume7.73M
Market Cap56.85B
P/E Ratio49.05
EPS$0.88
SectorHealth Care
Analyst Ratings
Strong Buy
34 analysts
Price Target
+413.6% upside
Current
$42.03
$42.03
Target
$215.88
$215.88
$132.52
$215.88 avg
$308.02
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 28.07B | 25.56B | 20.33B |
| Net Income | 1.14B | 937.57M | 3.37B |
| Profit Margin | 4.1% | 3.9% | 16.6% |
| EBITDA | 2.82B | 2.44B | 4.15B |
| Free Cash Flow | — | — | 3.45B |
| Rev Growth | +9.9% | +9.9% | -9.0% |
| Debt/Equity | 1.17 | 1.17 | 0.30 |
About Medline Inc-Cl A
Medline Industries, LP (Medline Inc.) is one of the largest privately held manufacturers and distributors of medical supplies and clinical solutions in the United States, headquartered in Northfield, Illinois. The company produces and distributes a comprehensive portfolio of medical and surgical products — including gloves, gowns, wound care supplies, and laboratory consumables — to hospitals, long-term care facilities, surgery centers, and physician offices. Medline operates its own manufacturing facilities and a nationwide distribution network, enabling direct-to-customer supply chain capabilities that differentiate it from pure-play distributors. Its scale across both manufacturing and distribution makes it a distinctive competitor to suppliers such as Cardinal Health and Medtronic's patient care business.
Health Care Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| UNH | UnitedHealth Group Inc | $272.28 | +1.02% | 21.7 | 261.12B |
| ABT | Abbott Laboratories | $104.06 | -0.75% | 28.3 | 184.68B |
| ISRG | Intuitive Surgical Inc | $471.91 | -1.28% | 59.8 | 170.78B |
| SYK | Stryker Corp | $328.51 | -1.23% | 39.5 | 128.28B |
| MDT | Medtronic Plc | $86.58 | -0.68% | 24.1 | 111.30B |
| MCK | Mckesson Corp | $881.94 | +0.56% | 25.1 | 109.03B |
MDLN Frequently Asked Questions
What does Medline do?
Medline operates at an unusual intersection in healthcare supply chains — it both manufactures medical products and distributes them, which most peers do only one or the other. The company produces gloves, gowns, wound care products, and surgical supplies in its own facilities, then delivers them directly to hospitals, nursing homes, and surgery centers through a nationwide logistics network. This vertically integrated model gives Medline pricing leverage and supply chain control that pure distributors like Cardinal Health or pure manufacturers like Medtronic cannot easily replicate.
Is MDLN stock a good investment?
As a relatively recent public company, Medline's stock doesn't yet have the long trading history investors typically use to assess valuation through cycles. The company's scale in medical supply — serving a substantial share of U.S. hospitals — provides volume stability, as healthcare demand doesn't disappear in economic downturns. Key risks include margin pressure from competitive pricing on commodity medical supplies, supply chain disruptions to overseas manufacturing, and the complexity of running a combined manufacturing-distribution model. Growth trajectory and market penetration are the primary metrics investors track.
Who are Medline's main competitors?
Cardinal Health and Medline overlap significantly in medical and surgical supply distribution to hospitals and long-term care facilities. Owens & Minor competes as a large-scale distributor of medical products. On the manufacturing side, Kimberly-Clark Professional and Ansell compete in protective apparel and gloves. McKesson, primarily known for pharmaceuticals, also distributes medical-surgical products in direct competition with Medline.
What makes MDLN stock unique?
What distinguishes Medline from most medical supply companies is the combination of manufacturing scale and distribution infrastructure under one roof — a model that took decades to build and would be extraordinarily capital-intensive to replicate. Its private-label product strategy means hospitals that rely on Medline brand products become deeply integrated customers, creating switching costs that go beyond simple price comparisons. The company also benefits from demographic tailwinds as aging populations in developed markets drive sustained demand for its core product lines.
What is the current share price of MDLN?
MDLN last closed at $42.03, down 1.06% in the most recent trading session. Over the past 52 weeks, the stock has traded between a low of $34.89 and a high of $50.88. The current price represents 45% of its 52-week range, which helps investors gauge where the stock sits relative to its recent trading history.
Is MDLN rated a buy or sell by analysts?
Among 34 analysts covering MDLN, the consensus rating is Strong Buy — 28 rate it a buy, 6 hold, and 0 sell. The average price target sits at $215.88, implying 414% upside from the current price. Keep in mind that analyst targets reflect 12-month expectations and can shift quickly after earnings reports or major company events.
What are Medline Inc-Cl A's earnings?
Medline Inc-Cl A generated $28.07B in revenue during fiscal year 2026, with $1.14B reaching the bottom line as net income. The net profit margin of 4.1% reflects the competitive nature of its industry.
How is MDLN valued compared to earnings?
MDLN trades at a P/E ratio of 49.05 on trailing earnings of $0.88 per share. That's above the S&P 500 historical average, suggesting the market expects above-average earnings growth ahead. Comparing this multiple against Health Care sector peers gives better context than the broad market alone, since P/E norms vary significantly across industries.